Kexon Pharmaceutical recently issued an announcement stating that Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” from the State Drug Administration to approve the clinical trial application for the company's self-developed drug GB08 injection. According to information, GB08 is expressed by the company by linking the human growth hormone (hGH) gene to the IgG4 subtype FC gene through DNA recombination technology, which can significantly improve product safety, patients' convenience and compliance with medication. If successfully marketed in the future, it will bring new treatments to children with growth hormone deficiency.
科兴制药：自研I类创新药长效生长激素临床试验申请获批
Kexon Pharmaceuticals: Self-developed Class I innovative drug long-term growth hormone clinical trial application approved
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.